SANDOZ GROUP AG

Strong first‑half 2026 results for Sandoz Group AG show biosimilar growth driving revenue up 10% and solid margins, while a $450M U.S. settlement clears legal hurdles for continued earnings momentum.

Discover how Sandoz’s $350 M acquisition of Just‑Evotec Biologics boosts its biosimilar manufacturing power and positions the company to tap a $300 bn market.

Explore how Sandoz Group AG’s launch of Afqlir and its sharp stock volatility reflect a high‑growth pharma strategy, yet raise caution for investors.

Sandoz Group AG has announced a potential acquisition of Just-Evotec Biologics, a biologics development and manufacturing facility in France, in a deal valued at approximately $300 million.